Hep B xAg Inhibitors

These compounds do not inhibit HBxAg directly but might reduce its expression or function by targeting the HBV life cycle or modifying host-virus interactions. For instance, nucleos(t)ide analogs work by mimicking the natural nucleotides that the viral DNA polymerase enzyme uses, leading to chain termination during viral DNA synthesis. This, in turn, can decrease the overall levels of viral proteins, including HBxAg. Kinase inhibitors, such as sorafenib, may impair signaling pathways that the virus hijacks for its replication and assembly, which could also impact HBxAg.

The compounds listed above include a mix of nucleoside/nucleotide analogs, kinase inhibitors, natural compounds with antiviral properties, and immunomodulators. Each of these compounds interferes with the viral life cycle at different stages or enhances the host immune response to fight the infection. For example, nucleoside/nucleotide analogs such as lamivudine and entecavir are incorporated into the viral DNA by the viral DNA polymerase, leading to premature termination of DNA synthesis. Agents like sorafenib target cellular processes that may be essential for HBV replication, affecting HBxAg indirectly.